BioNTech SE (BNTX) Net Margin (2018 - 2025)

BioNTech SE has disclosed Net Margin across 8 years of filings, most recently posting 16.51% for Q4 2025.

• Net Margin for Q4 2025 came in at 16.51%, down 1652.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 36.88% (down 3686.0% YoY), and the FY2025 annual result was 1285.62%, down 126053.0% from the prior year.
• Net Margin came in at 16.51% for Q4 2025 at BioNTech SE, down from 5.14% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 105.28% in Q1 2021 to a low of 5369.23% in Q2 2025.
• The 5-year median for Net Margin is 16.79% (2021), against an average of 550.08%.
• Peak annual rise in Net Margin reached 137759 bps in 2025, while the deepest fall reached 474468 bps in 2025.
• BioNTech SE's Net Margin stood at 0.0% in 2021, then jumped by 166085745 bps to 95.05% in 2022, then slumped by 67 bps to 30.96% in 2023, then tumbled by 100 bps to 0.01% in 2024, then tumbled by 210037 bps to 16.51% in 2025.
• The last three Net Margin figures came in at 16.51% (Q4 2025), 5.14% (Q3 2025), and 5369.23% (Q2 2025), per Business Quant data.